HK Stock Market Move | AIM Vaccine (06660) rose more than 8% during the trading session, recently completing a board of directors change and accelerating the company's "H+A" strategic layout.

AIM VACCINE (06660) rose more than 8% during trading, as of the time of writing, it has risen by 7.65% to HK$1.83. In terms of news, recently, AIM VACCINE held its 2025 shareholder annual meeting, completing the election of the board of directors and various professional committees. In this election, 57-year-old internal R&D veteran Wu Jinan was appointed as the CEO, chief scientist, and director of the R&D management committee, attracting much attention. It is reported that AIM VACCINE has a total of 20 vaccines under research and development, with 24 clinical approvals. In January of this year, the company's globally first researched serum-free iterative rabies vaccine successfully passed drug clinical trial site inspection and drug registration production site inspection. Currently, there is no serum-free rabies vaccine approved and marketed globally, and this product is expected to fill a market gap once it is released. It is worth noting that at the end of March this year, AIM VACCINE announced that its board of directors had deliberated and passed a resolution to issue no more than 40 million shares of domestic stock, and planned to promote the listing of domestic stock on the New Third Board and further apply for an A-share listing on the North Stock Exchange. If AIM VACCINE achieves its "H+A" strategic layout, it will not only benefit the company's valuation on the Hong Kong stock market and the activity of the secondary market but also its brand value and business are expected to have rapid development.